AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2414966 — intervention group
Group type: EXPERIMENTAL
Intervention: 32% dextran 70 (HyskonR)
Number of subjects: 105
Study 2414966 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 105
Study 30827574 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-based cases
Number of subjects: 0
Study 30827574 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulation
Number of subjects: 0
Study 30827574 — intervention group
Group type: COMPARATOR
Intervention: Order of educational intervention
Number of subjects: 0
Study 30411125 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health promotion project (6 months duration)
Number of subjects: 322
Study 30411125 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 322
Study 27512975 — intervention group
Group type: COMPARATOR
Intervention: light‐intensity walking (3.2 km/h for 3 min)
Number of subjects: 24
Study 27512975 — intervention group
Group type: COMPARATOR
Intervention: simple resistance activities (SRA) for 3 min
Number of subjects: 24
Study 27512975 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT (uninterrupted sitting)
Number of subjects: 24
Study 23947915 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin (ROX)
Number of subjects: 31
Study 23947915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 22713691 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretransplantation ATG-Fresenius (ATG-F)
Number of subjects: 201
Study 22713691 — intervention group
Group type: COMPARATOR
Intervention: Standard graft-versus-host-disease (GVHD) prophylaxis
Number of subjects: 201
Study 19996984 — intervention group
Group type: EXPERIMENTAL
Intervention: Fospropofol 6.5 mg/kg
Number of subjects: 314
Study 19996984 — intervention group
Group type: EXPERIMENTAL
Intervention: Fospropofol 2 mg/kg
Number of subjects: 314
Study 19996984 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.02 mg/kg
Number of subjects: 314
Study 18713473 — intervention group
Group type: EXPERIMENTAL
Intervention: Reattribution training
Number of subjects: 74
Study 15976197 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (0.5 microg . kg(‐1) . min(‐1))
Number of subjects: 140
Study 15976197 — intervention group
Group type: COMPARATOR
Intervention: MR(+) group (no intervention)
Number of subjects: 140
Study 15976197 — intervention group
Group type: EXPERIMENTAL
Intervention: M+MR(+) group (milrinone)
Number of subjects: 140
Study 12629232 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with mild PD
Number of subjects: 16
Study 12629232 — intervention group
Group type: COMPARATOR
Intervention: Healthy seniors
Number of subjects: 16
Study 10486643 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated hypertensives (G1)
Number of subjects: 1160
Study 10486643 — intervention group
Group type: COMPARATOR
Intervention: Known but untreated hypertensives (G2)
Number of subjects: 1160
Study 10486643 — intervention group
Group type: COMPARATOR
Intervention: Newly diagnosed hypertensives (G3)
Number of subjects: 1160
Study 8903447 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cytology indicating allergic pathogenesis
Number of subjects: 40
Study 8903447 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal eosinophils
Number of subjects: 40
Study 8903447 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergic rhinitis with nasal eosinophilia
Number of subjects: 40
Study 1721176 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrially-tracked ventricular pacing (Group I)
Number of subjects: 13
Study 1721176 — intervention group
Group type: COMPARATOR
Intervention: Rate adaptive AV delay (Group II)
Number of subjects: 13
Study 31967678 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy (HIPEC) added to interval cytoreductive surgery (CRS)
Number of subjects: 0
Study 31967678 — intervention group
Group type: COMPARATOR
Intervention: Interval cytoreductive surgery (CRS) alone
Number of subjects: 0
Study 29650559 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD care bundle intervention delivered to general practitioners (GPs) and practice assistants
Number of subjects: 216
Study 29650559 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 216
Study 27488236 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 vitamin D3-enhanced eggs/week
Number of subjects: 55
Study 27488236 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 25(OH)D3-enhanced eggs/week
Number of subjects: 55
Study 27488236 — intervention group
Group type: COMPARATOR
Intervention: Control group (≤2 eggs/week)
Number of subjects: 55
Study 25176395 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration followed by PCI
Number of subjects: 7244
Study 25176395 — intervention group
Group type: COMPARATOR
Intervention: PCI alone
Number of subjects: 7244
Study 22486135 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin
Number of subjects: 200
Study 22486135 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 200
Study 20495139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 20495139 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 25 μg/min
Number of subjects: 101
Study 20495139 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 50 μg/min
Number of subjects: 101
Study 20495139 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 75 μg/min
Number of subjects: 101
Study 20495139 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 100 μg/min
Number of subjects: 101
Study 20495139 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (all doses)
Number of subjects: 101
Study 20495139 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 101
Study 19114405 — intervention group
Group type: EXPERIMENTAL
Intervention: COF (250 mL of black coffee)
Number of subjects: 8
Study 19114405 — intervention group
Group type: EXPERIMENTAL
Intervention: COF+SUC (black coffee sweetened with 10 g of sucrose)
Number of subjects: 8
Study 19114405 — intervention group
Group type: EXPERIMENTAL
Intervention: DECAF (decaffeinated coffee)
Number of subjects: 8
Study 19114405 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA (black tea)
Number of subjects: 8
Study 19114405 — intervention group
Group type: EXPERIMENTAL
Intervention: SUC (10 g sucrose)
Number of subjects: 8
Study 19114405 — intervention group
Group type: COMPARATOR
Intervention: CON (hot water)
Number of subjects: 8
Study 15953302 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-administered relaxation training
Number of subjects: 288
Study 15953302 — intervention group
Group type: EXPERIMENTAL
Intervention: School-nurse administered relaxation training
Number of subjects: 288
Study 15953302 — intervention group
Group type: EXPERIMENTAL
Intervention: Any form of relaxation training
Number of subjects: 288
Study 15953302 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation treatment
Number of subjects: 288
Study 15953302 — intervention group
Group type: COMPARATOR
Intervention: Attention-control (ATCO) approaches or self-monitoring (SM) of headaches
Number of subjects: 288
Study 12578769 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 41
Study 12578769 — intervention group
Group type: COMPARATOR
Intervention: N-butyl-2-cyanoacrylate
Number of subjects: 41
Study 10029463 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical parameters for predicting disc displacement with reduction
Number of subjects: 160
Study 10029463 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical parameters for predicting disc displacement without reduction
Number of subjects: 160
Study 10029463 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate zone MRI criterion
Number of subjects: 160
Study 10029463 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of the most sensitive clinical items
Number of subjects: 160
Study 8873389 — intervention group
Group type: EXPERIMENTAL
Intervention: 23‐valent pneumococcal polysaccharide vaccine
Number of subjects: 150
Study 8873389 — intervention group
Group type: COMPARATOR
Intervention: Meningococcal polysaccharide vaccine
Number of subjects: 150
Study 1745841 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromhexine (30 mg capsules three times daily)
Number of subjects: 88
Study 1745841 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched placebo capsules)
Number of subjects: 88
Study 7050705 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (180 g) in divided doses over three days after phenobarbital infusion
Number of subjects: 6
Study 31959349 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus carboplatin and etoposide (CP/ET)
Number of subjects: 394
Study 31959349 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus carboplatin and etoposide (CP/ET)
Number of subjects: 394
Study 31060589 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologically informed physical therapy (PIPT) training program
Number of subjects: 0
Study 28554177 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic perconditioning (RIPerC)
Number of subjects: 102
Study 24691853 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sucralfate four times a day for 7 days
Number of subjects: 50
Study 24691853 — intervention group
Group type: COMPARATOR
Intervention: Control group (no topical treatment)
Number of subjects: 50
Study 25158046 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity, task-oriented, visual feedback training with a video game balance board (Nintendo Wii) for 12 weeks.
Number of subjects: 27
Study 25158046 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 weeks without intervention).
Number of subjects: 27
Study 22024027 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip (period 1)
Number of subjects: 75
Study 22024027 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip (period 2)
Number of subjects: 75
Study 22024027 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip (period 3)
Number of subjects: 75
Study 22024027 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip (all periods)
Number of subjects: 75
Study 19846848 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-intensity continuous renal-replacement therapy (40 ml/kg/hour)
Number of subjects: 1508
Study 19846848 — intervention group
Group type: COMPARATOR
Intervention: Lower-intensity continuous renal-replacement therapy (25 ml/kg/hour)
Number of subjects: 1508
Study 19846848 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-intensity continuous renal-replacement therapy
Number of subjects: 1508
Study 19846848 — intervention group
Group type: COMPARATOR
Intervention: Lower-intensity continuous renal-replacement therapy
Number of subjects: 1508
Study 17367361 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker diagnostics (Kappa 7‐900, Medtronic, Inc.) detecting atrial high rate episodes (AHRE)
Number of subjects: 427
Study 17367361 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (patients with prior AT history)
Number of subjects: 427
Study 17367361 — intervention group
Group type: COMPARATOR
Intervention: Group I (patients without prior AT history)
Number of subjects: 427
Study 17367361 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after the first month post-implant
Number of subjects: 427
Study 17367361 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 427
Study 17367361 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior history of AT
Number of subjects: 427
Study 17367361 — intervention group
Group type: EXPERIMENTAL
Intervention: AHRE diagnostics
Number of subjects: 427
Study 16379582 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatibant 3.75 mg
Number of subjects: 25
Study 16379582 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatibant 22.5 mg
Number of subjects: 25
Study 16379582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 16379582 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatibant (both doses)
Number of subjects: 25
Study 11952185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study 11952185 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 0
Study 9814463 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (Hex; 2 microg/kg, i.v.)
Number of subjects: 18
Study 9814463 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1 microg/kg, i.v.)
Number of subjects: 18
Study 7657416 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi‐solid carbohydrate feeding
Number of subjects: 31
Study 7657416 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid carbohydrate feeding
Number of subjects: 31
Study 7657416 — intervention group
Group type: COMPARATOR
Intervention: Liquid placebo
Number of subjects: 31
Study 2504034 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 30
Study 2504034 — intervention group
Group type: COMPARATOR
Intervention: Lithium (Li) added to tricyclic antidepressant
Number of subjects: 30
Study 975039 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly combination chemotherapy
Number of subjects: 0
Study 975039 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent combination chemotherapy
Number of subjects: 0
Study 975039 — intervention group
Group type: COMPARATOR
Intervention: Single-drug chemotherapy administered sequentially
Number of subjects: 0
Study 975039 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (both weekly and intermittent)
Number of subjects: 0
Study 30560426 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic capsule (Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, 2 × 10^9 CFU/g each, plus 0.8 g/day of inulin)
Number of subjects: 60
Study 30560426 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic capsule
Number of subjects: 60
Study 28459958 — intervention group
Group type: EXPERIMENTAL
Intervention: TRV027 1 mg/h
Number of subjects: 621
Study 28459958 — intervention group
Group type: EXPERIMENTAL
Intervention: TRV027 5 mg/h
Number of subjects: 621
Study 28459958 — intervention group
Group type: EXPERIMENTAL
Intervention: TRV027 25 mg/h
Number of subjects: 621
Study 28459958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 621
Study 26036529 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-free regimen (tacrolimus, mycophenolic acid, basiliximab induction, steroids for 3 days)
Number of subjects: 428
Study 26036529 — intervention group
Group type: COMPARATOR
Intervention: Steroid maintenance regimen (tacrolimus, mycophenolic acid, basiliximab induction, steroids maintenance)
Number of subjects: 428
Study 26036529 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-free regimen
Number of subjects: 428
Study 26036529 — intervention group
Group type: COMPARATOR
Intervention: Steroid maintenance regimen
Number of subjects: 428
Study 23561715 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 120
Study 23561715 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 120
Study 22384550 — intervention group
Group type: EXPERIMENTAL
Intervention: Weiyan serial recipes (WYSR)
Number of subjects: 150
Study 22384550 — intervention group
Group type: COMPARATOR
Intervention: Weifuchun Pill
Number of subjects: 150
Study 19211408 — intervention group
Group type: EXPERIMENTAL
Intervention: EUSOL (Edinburgh University Solution of Lime)
Number of subjects: 0
Study 19211408 — intervention group
Group type: COMPARATOR
Intervention: Sugar
Number of subjects: 0
Study 16679088 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 260
Study 15018289 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-body cooling (LC)
Number of subjects: 8
Study 15018289 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-body cooling (UC)
Number of subjects: 8
Study 15018289 — intervention group
Group type: COMPARATOR
Intervention: No cooling control (CON)
Number of subjects: 8
Study 11461038 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing Oxylog mask, heart rate monitor, and Oxylog instrument
Number of subjects: 17
Study 11461038 — intervention group
Group type: COMPARATOR
Intervention: Wearing only heart monitor (Control)
Number of subjects: 17
Study 9726810 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (with antioxidants, amino acids, and nimodipine)
Number of subjects: 35
Study 9726810 — intervention group
Group type: COMPARATOR
Intervention: Control (no selenium supplementation)
Number of subjects: 35
Study 8026054 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary urokinase (250,000 U in divided doses)
Number of subjects: 469
Study 8026054 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary urokinase (500,000 U in divided doses)
Number of subjects: 469
Study 8026054 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary urokinase
Number of subjects: 469
Study 8026054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 469
Study 2740970 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical anastomosis (CA)
Number of subjects: 92
Study 2740970 — intervention group
Group type: COMPARATOR
Intervention: Thoracic anastomosis (TA)
Number of subjects: 92
Study 4138966 — intervention group
Group type: COMPARATOR
Intervention: CCNU (130 mg/m2 orally every 6 weeks)
Number of subjects: 58
Study 4138966 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 azacytidine (60 mg/m2 intravenously daily for 10 days and twice weekly thereafter)
Number of subjects: 58
Study 4138966 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (two dose schedules)
Number of subjects: 58
Study 4138966 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunologic skin testing
Number of subjects: 58
Study 29877722 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow milk-based nutrition (0% to 100%)
Number of subjects: 260
Study 28605740 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine with acotiamide
Number of subjects: 50
Study 28605740 — intervention group
Group type: COMPARATOR
Intervention: Placebo with acotiamide
Number of subjects: 50
Study 26154454 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) application (6J)
Number of subjects: 79
Study 26154454 — intervention group
Group type: COMPARATOR
Intervention: Placebo application
Number of subjects: 79
Study 26154454 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 79
Study 23454058 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir (400 mg TID)
Number of subjects: 0
Study 23454058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21673013 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial release techniques
Number of subjects: 86
Study 21673013 — intervention group
Group type: COMPARATOR
Intervention: Sham short‐wave and ultrasound electrotherapy
Number of subjects: 86
Study 18434021 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo method (skin-to-skin contact)
Number of subjects: 95
Study 18434021 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose (1 ml, 25%)
Number of subjects: 95
Study 18434021 — intervention group
Group type: COMPARATOR
Intervention: Isolette (no analgesia)
Number of subjects: 95
Study 16868824 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmint plus Loperamide or Psyllium
Number of subjects: 32
Study 16868824 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Loperamide or Psyllium
Number of subjects: 32
Study 12971247 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study 12971247 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel agents and/or combination therapies
Number of subjects: 0
Study 10233189 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC400OM: RBC 400 mg b.d., oxytetracycline 500 mg q.d.s.
Number of subjects: 183
Study 10233189 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC400SM: RBC 400 mg b.d., spiramycin 1 g q.d.s.
Number of subjects: 183
Study 10233189 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC200OM: RBC 200 mg q.d.s., oxytetracycline 500 mg q.d.s.
Number of subjects: 183
Study 10233189 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC200SM: RBC 200 mg q.d.s., spiramycin 1 g q.d.s.
Number of subjects: 183
Study 10233189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulcer patients
Number of subjects: 183
Study 10233189 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ulcer patients
Number of subjects: 183
Study 10233189 — intervention group
Group type: EXPERIMENTAL
Intervention: Never smoked
Number of subjects: 183
Study 10233189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex-smokers
Number of subjects: 183
Study 10233189 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 183
Study 10233189 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 183
Study 9119918 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 4-16 mg/day
Number of subjects: 7
Study 9119918 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 10-20 mg/day
Number of subjects: 7
Study 9119918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 9119918 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 7
Study 9119918 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 7
Study 2119562 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 25
Study 2119562 — intervention group
Group type: COMPARATOR
Intervention: No Mannitol
Number of subjects: 25
Study 7407606 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (4 mg)
Number of subjects: 0
Study 7407606 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0
Study 31230881 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose formulation of the EV71 vaccine
Number of subjects: 36
Study 31230881 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose formulation of the EV71 vaccine
Number of subjects: 36
Study 31230881 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 36
Study 27710006 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong Families Strong Forces Parenting Program
Number of subjects: 115